Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Still Overpatented, Still Overpriced
Merck’s Scheme to Product Hop Keytruda
How Celgene and Bristol Myers Squibb Used Volume Restrictions to Delay Revlimid Competition
How Pharma and Its Consultants Abuse the Patent System
We Need More Drug Patent Data
Investigating the pharmaceutical industry’s drug patenting practices
Five Patent Predictions for 2025
The Year in Patent Reform
The real legacy of the Hatch-Waxman Act
Why Current Legislation to Prevent Patent Thickets Are a Good Start — But Not Enough